Effects of St. John's wort extract on indinavir pharmacokinetics in rats: Differentiation of intestinal and hepatic impacts

Life Sciences

Volumn 85, Issue 7-8, 2009, Pages 296-302

  Ho, Yunn Fang ^a   Huang, Da Kong ^a   Hsueh, Wei Cherng ^a   Lai, Ming Yen ^a   Yu, Hsiu Ying ^a   Tsai, Tung Hu ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bioavailability; Cytochrome P450; Drug herb interaction; Mechanism

Indexed keywords

CYTOCHROME P450; HYPERICUM PERFORATUM EXTRACT; INDINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FIRST PASS EFFECT; FLOW RATE; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INTESTINE PERFUSION; LIVER; MALE; NONHUMAN; RAT; SMALL INTESTINE; SPECTROPHOTOMETRY; TREATMENT DURATION; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HERB-DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HYPERICUM; INDINAVIR; MALE; MICROSOMES, LIVER; PLANT EXTRACTS; RATS; RATS, WISTAR; TIME FACTORS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 67651175832     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.06.008     Document Type: Article

References (40)

1. Bilia A.R., Gallori S., and Vincieri F.F. St. John's wort and depression: efficacy, safety and tolerability - an update. Life Sciences 70 (2002) 3077-3096
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 (1976) 248-254
3. Bray B.J., and Rosengren R.J. Retinol potentiates acetaminophen-induced hepatotoxicity in the mouse: mechanistic studies. Toxicology and Applied Pharmacology 173 (2001) 129-136
4. Bray B.J., Brennan N.J., Perry N.B., Menkes D.B., and Rosengren R.J. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. Life Sciences 70 (2002) 1325-1335
5. Bray B.J., Perry N.B., Menkes D.B., and Rosengren R.J. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicological Sciences 66 (2002) 27-33
6. Bressler R. Herb-drug interactions. St. John's wort and prescription medications. Geriatrics 60 (2005) 21-23
7. Bruno J.J., and Ellis J.J. Herbal use among US elderly: 2002 National Health Interview Survey. Annals of Pharmacotherapy 39 (2005) 643-648
8. Budzinski J.W., Foster B.C., Vandenhoek S., and Arnason J.T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7 (2000) 273-282
9. Canter P.H., and Ernst E. Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs & Aging 21 (2004) 597-605
10. Dhalla S., Chan K.J., Montaner J.S., and Hogg R.S. Complementary and alternative medicine use in British Columbia - a survey of HIV positive people on antiretroviral therapy. Complementary Therapies Clinical Practice 12 (2006) 242-248
11. Dresser G.K., Schwarz U.I., Wilkinson G.R., and Kim R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73 (2003) 41-50
12. Dürr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., and Fattinger K. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clinical Pharmacology and Therapeutics 68 (2000) 598-604
13. Ekins S., and Wrighton S.A. Application of in silico approaches to predicting drug-drug interaction. Journal of Pharmacological and Toxicological Methods 45 (2001) 65-69
14. Elmer G.W., Lafferty W.E., Tyree P.T., and Lind B.K. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Annals of Pharmacotherapy 41 (2007) 1617-1624
15. Guengerich F.P. Analysis and characterization of enzymes and nucleic acids. In: Hayes A.W. (Ed). Principles and Methods of Toxicology (2001), Taylor & Francis, Philadelphia 1625-1687
16. Guh J.Y., Chen H.C., Tsai J.F., and Chuang L.Y. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. American Journal of Kidney Diseases 49 (2007) 626-633
17. Gurley B.J., Gardner S.F., Hubbard M.A., Williams K., Gentry B., Cui Y., and Ang C.Y.W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical Pharmacology and Therapeutics 72 (2002) 276-287
18. Ho Y.F., Lai M.Y., Yu H.Y., Huang D.K., Hsueh W.C., Tsai T.H., and Lin C.C. Application of rat in situ single-pass intestinal perfusion in the evaluation of pre-systemic extraction of indinavir under different perfusion rates. Journal of the Formosan Medical Association 107 (2008) 37-45
19. Kelly J.P., Kaufman D.W., Kelley K., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent trends in use of herbal and other natural products. Archives of Internal Medicine 165 (2005) 281-286
20. Kennedy J. Herb and supplement use in the US adult population. Clinical Therapeutics 27 (2005) 1847-1858
21. Lee H.B., and Blaufox M.D. Blood volume in the rat. Journal of Nuclear Medicine 25 (1985) 72-76
22. Lewis D.F.V. COMPACT: a structural approach to the modeling of cytochromes P450 and their interactions with xenobiotics. Journal of Chemical Technology & Biotechnology 76 (2001) 237-244
23. Li X., Benjamin I.S., Naftalin R., and Alexander B. Location and function of intrahepatic shunts in anaesthetised rats. Gut 52 (2003) 1339-1346
24. Lin J.H., Chiba M., Balani S.K., Chen I.W., Kwei G.Y., Vastag K.J., and Nishime J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition 24 (1996) 1111-1120
25. Markowitz J.S., DeVane C.L., Boulton D.W., Carson S.W., Nahas Z., and Risch S.C. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sciences 66 (2000) PL133-PL139
26. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.S., and Chavin K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. Journal of the American Medical Association 290 (2003) 1500-1504
27. Mills E., Wu P., Johnston B.C., Gallicano K., Clarke M., and Guyatt G. Natural health product-drug interactions: a systematic review of clinical trials. Therapeutic Drug Monitoring 27 (2005) 549-557
28. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., and Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 7500-7502
29. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. Journal of Pharmacology and Experimental Therapeutics 294 (2000) 88-95
30. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., and Falloon J. Indinavir concentrations and St. John's wort. Lancet 355 (2000) 547-548
31. Richardson P.D., and Withrington P.G. Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology 81 (1981) 159-173
32. Roby C.A., Anderson G.D., Kantor E., Dryer D.A., and Burstein A.H. St John's wort: effect on CYP3A4 activity. Clinical Pharmacology and Therapeutics 67 (2000) 451-457
33. Ross S., Simpson C.R., and McLay J.S. Homoeopathic and herbal prescribing in general practice in Scotland. British Journal of Clinical Pharmacology 62 (2006) 647-652
34. Schenkman J.B., and Jansson I. Measurement of cytochrome P-450. In: Maines M.D., Costa L.G., Hodgson E., Reed D.J., and Sipes I.G. (Eds). Current Protocols in Toxicology (1999), John Wiley & Sons, New York 4.1.8-4.1.9
35. Schnuda N.D. Circulation and migration of small blood lymphocytes in the rat. I. Kinetics of lymphocyte circulation in the lymphoid organs. American Journal of Pathology 93 (1978) 623-638
36. Shibata N., Matsumura Y., Okamoto H., Kawaguchi Y., Ohtani A., Yoshikawa Y., and Takada K. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors. Journal of Pharmacy and Pharmacology 52 (2000) 1239-1246
37. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., Sardana V.V., Schlabach A.J., Graham P.I., Condra J.H., Gotlib L., Holloway M.K., Lin J., Chen I.W., Vastag K., Ostovic D., Anderson P.S., Emini E.A., and Huff J.R. L-735, 524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 4096-2100
38. Wang Z., Gorski J.C., Hamman M.A., Huang S.M., Lesko L.J., and Hall S.D. The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70 (2001) 317-326
39. Zhou S., Gao Y., Jiang W., Huang M., Xu A., and Paxton J.W. Interactions of herbs with cytochrome P450. Drug Metabolism Reviews 35 (2003) 35-98
40. Zou L., Harkey M.R., and Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sciences 71 (2002) 1579-1589